IRIS
AIMO, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.049
EU - Europa 5.042
AS - Asia 1.944
SA - Sud America 28
Continente sconosciuto - Info sul continente non disponibili 18
AF - Africa 14
OC - Oceania 8
Totale 13.103
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.792
IT - Italia 1.586
GB - Regno Unito 1.167
SG - Singapore 1.130
DE - Germania 503
IE - Irlanda 419
RU - Federazione Russa 396
UA - Ucraina 364
CN - Cina 332
CA - Canada 247
VN - Vietnam 223
SE - Svezia 179
FI - Finlandia 121
HK - Hong Kong 97
DK - Danimarca 64
FR - Francia 62
PK - Pakistan 52
NL - Olanda 40
IN - India 33
AT - Austria 22
CH - Svizzera 22
BE - Belgio 20
EU - Europa 17
RO - Romania 16
LT - Lituania 15
ES - Italia 13
ID - Indonesia 12
IR - Iran 12
BD - Bangladesh 11
BR - Brasile 11
JP - Giappone 11
PL - Polonia 9
AR - Argentina 7
AM - Armenia 6
AU - Australia 6
EG - Egitto 6
SK - Slovacchia (Repubblica Slovacca) 5
TR - Turchia 4
CO - Colombia 3
CZ - Repubblica Ceca 3
EC - Ecuador 3
HU - Ungheria 3
KG - Kirghizistan 3
MX - Messico 3
PA - Panama 3
PE - Perù 3
TH - Thailandia 3
TW - Taiwan 3
CI - Costa d'Avorio 2
KR - Corea 2
MA - Marocco 2
MT - Malta 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PT - Portogallo 2
RS - Serbia 2
SA - Arabia Saudita 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
CL - Cile 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
NO - Norvegia 1
SC - Seychelles 1
ZA - Sudafrica 1
Totale 13.103
Salva come PNG Salva come JPEG
Città #
Singapore 922
Chandler 562
Southend 543
Fairfield 462
San Mateo 451
Dublin 415
Woodbridge 356
Houston 319
Cambridge 316
Wilmington 243
Falls Church 237
Boardman 230
Seattle 230
Portsmouth 227
Stevenage 215
Ann Arbor 212
Ashburn 206
Ottawa 202
Jacksonville 175
Dearborn 156
Lawrence 155
Pisa 144
Rome 136
Milan 124
Dong Ket 117
Santa Clara 113
Beijing 110
Florence 78
Helsinki 76
San Diego 64
London 61
Munich 55
Hong Kong 46
Los Angeles 44
Brooklyn 42
Fremont 38
Central District 34
Bologna 33
Palermo 31
Livorno 28
Washington 27
Assago 26
Frankfurt am Main 26
Lappeenranta 26
Redwood City 26
Naples 25
Toronto 25
Norwalk 23
Shanghai 22
Genoa 21
Old Bridge 21
Brussels 19
Buti 19
Lucca 18
Redmond 17
Shenzhen 17
Guangzhou 16
Bari 15
Dallas 14
Islamabad 14
Verona 14
Zhengzhou 14
Hounslow 13
Medolago 13
Amsterdam 12
Nanjing 12
West Jordan 12
Chiswick 11
Faisalabad 11
Parma 11
Vienna 11
Bucharest 10
Cascina 10
Catania 10
Nuremberg 10
Padova 10
Turin 10
Chicago 9
Forlì 9
Lahore 9
Montréal 9
Pescia 9
Brescia 8
Dongguan 8
New Delhi 8
Venice 8
Zurich 8
Acton 7
Fort Worth 7
Kilburn 7
Malang 7
New York 7
Reggio Emilia 7
Taranto 7
Tehran 7
Wandsworth 7
Wuhan 7
Veglie 6
Warsaw 6
Yerevan 6
Totale 8.992
Salva come PNG Salva come JPEG
Nome #
[ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients] 199
Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease 183
Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences 175
Peripheral reflex feedbacks in chronic heart failure: Is it time for a direct treatment? 174
Treating chemoreflex in heart failure: modulation or demolition? 167
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 167
Building medical knowledge from real world registries: The case of heart failure 166
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 163
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis 161
The heart after idarubicin overdose. Cardiac death in a patient with acute promyelocitic leukaemia 158
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 157
Myocardial damage in a mitochondrial myopathy patient with increased ergoreceptor sensitivity and sympatho-vagal imbalance 156
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 153
Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure 152
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 147
Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning 134
Cardiac light-chain deposition disease relapsing in the transplanted heart 131
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 129
Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis 121
COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead 120
Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy 117
Sex-related differences in chronic heart failure 114
A simple echocardiographic score to rule out cardiac amyloidosis 112
How to take arms against central apneas in heart failure 104
Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease 104
"Targeting and Treating Apneas" in "The Breathless Heart: Apneas in Heart Failure" 100
Heart, kidney and FGF23: Les liaisons dangereuses 99
Exercise intolerance in heart failure with preserved ejection fraction: A reappraisal of central mechanisms? 97
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 97
Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry 96
Unmet needs in end-of-life care for heart failure patients 95
NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure 94
Noncardiovascular death after acute heart failure. Do not lose the war while fighting for the failing heart 93
Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure 92
High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure 92
The Importance of Visceral Feedbacks: Focus on Chemoreceptors 90
Is fat good for arrhythmias in ischemic heart failure? Another face of the obesity paradox 88
Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction 88
Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy 86
The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers 85
Procalcitonin, white blood cell count and C-reactive protein as predictors of S. aureus infection and mortality in infective endocarditis 84
Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure 84
The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy 83
Body mass index and outcomes in ischaemic versus non-ischaemic heart failure across the spectrum of ejection fraction 83
Management of complications of cardiac amyloidosis: 10 questions and answers 82
Cardiac troponins as biomarkers for cardiac disease 82
Polymorphisms in the eNOS gene and the risk of coronary artery disease: Making the case for genome-wide association studies 79
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 79
N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure 77
Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences 77
sST2 Predicts Outcome in Chronic Heart Failure Beyond NT−proBNP and High-Sensitivity Troponin T 76
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 76
Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias 76
Amiodarone as a possible therapy for coronavirus infection 75
Left ventricular ejection fraction for risk stratification in chronic systolic heart failure 74
Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis 74
Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC) 73
Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis 70
Therapies for cardiac light chain amyloidosis: An update 70
The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target? 70
The prognostic benefit of cardiac resynchronization therapy is greater in concordant vs. discordant left bundle branch block in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT) 70
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies 70
Wet is bad: Residual congestion predicts worse prognosis in acute heart failure 69
Quality of life and outcome in heart failure with preserved ejection fraction: When sex matters 68
Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome 68
Sex-related differences in chronic heart failure 67
Biomarkers for the diagnosis and management of heart failure 67
Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis 63
How much is it to mend a broken heart? Results from the US Nationwide Readmission Database 62
Treatment of cardiac transthyretin amyloidosis: an update 61
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 61
Atrial amyloidosis: mechanisms and clinical manifestations 60
Position paper ANMCO: Impiego di vericiguat nello scompenso cardiaco: dalle evidenze al posizionamento terapeutico 59
Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week 58
Molecular autopsy of sudden cardiac death in the genomics era 58
The Fondazione Toscana Gabriele Monasterio app: a digital health system to improve wellbeing of inpatients with heart or lung disease 57
Longer sleep duration and poor sleep quality as risk factors for hyperlipidaemia 57
Use of biomarkers to diagnose and manage cardiac amyloidosis 57
ANMCO/ELAS/SIBioC Consensus Document: Biomarkers in heart failure 56
Role of Imaging in Cardiomyopathies 55
Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women 55
Cardiovascular disease and COVID-19: les liaisons dangereuses 55
Biomarkers for the diagnosis and management of heart failure: New frontiers 55
A simple echocardiographic score to rule out cardiac amyloidosis 54
Underprescription of disease-modifying drugs in chronic heart failure: More is better? 54
Morphologies and prognostic significance of left ventricular volume/time curves with cardiac magnetic resonance in patients with non-ischaemic heart failure and left bundle branch block 53
Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance 53
Factors for heterogeneous outcomes of angina and myocardial ischemia without obstructive coronary atherosclerosis 53
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 53
Sacubitril/Valsartan, Cardiac Fibrosis, and Remodeling in Heart Failure 52
Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction 52
Subclinical cardiac damage in cancer patients before chemotherapy 52
Current and emerging drug targets in heart failure treatment 52
Cardiovascular magnetic resonance for the diagnosis and management of heart failure with preserved ejection fraction 51
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis 51
Cocaine and methamphetamine use and hospitalization for acute heart failure: Epidemiological evidence from a nationwide dataset 50
Aspirin and Prognosis in Heart Failure: A Question of Power 50
Aspirin for primary cardiovascular prevention: Why the wonder drug should not be precipitously dismissed 48
Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis 47
Colchicine for the treatment of coronary artery disease 46
Totale 8.879
Salva come PNG Salva come JPEG
Categoria #
all - tutte 137.451
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 137.451
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020627 0 0 0 0 0 134 120 82 131 24 42 94
2020/20212.357 195 209 96 208 108 321 143 129 217 158 252 321
2021/20222.538 177 295 65 231 108 145 298 491 203 285 52 188
2022/20231.732 162 165 75 154 210 208 42 155 341 43 121 56
2023/20241.762 107 49 336 122 75 154 106 71 88 96 95 463
2024/20252.993 220 243 878 362 665 625 0 0 0 0 0 0
Totale 13.458